Milestone Pharmaceuticals Inc. (MIST): Price and Financial Metrics
GET POWR RATINGS... FREE!
MIST Stock Summary
- MIST's went public 2.89 years ago, making it older than merely 8.67% of listed US stocks we're tracking.
- For MIST, its debt to operating expenses ratio is greater than that reported by merely 5.93% of US equities we're observing.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.05 for Milestone Pharmaceuticals Inc; that's greater than it is for only 6.26% of US stocks.
- If you're looking for stocks that are quantitatively similar to Milestone Pharmaceuticals Inc, a group of peers worth examining would be ADAP, DCPH, BCDA, MIRM, and MRUS.
- MIST's SEC filings can be seen here. And to visit Milestone Pharmaceuticals Inc's official web site, go to www.milestonepharma.com.
MIST Valuation Summary
- In comparison to the median Healthcare stock, MIST's price/sales ratio is 6.61% higher, now standing at 12.1.
- Over the past 28 months, MIST's price/earnings ratio has gone up 9.7.
- Over the past 28 months, MIST's EV/EBIT ratio has gone up 9.1.
Below are key valuation metrics over time for MIST.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MIST | 2021-08-31 | 12.1 | 1.3 | -5.6 | -2.6 |
| MIST | 2021-08-30 | 12.1 | 1.3 | -5.6 | -2.6 |
| MIST | 2021-08-27 | 12.5 | 1.3 | -5.8 | -2.8 |
| MIST | 2021-08-26 | 12.2 | 1.3 | -5.7 | -2.7 |
| MIST | 2021-08-25 | 12.0 | 1.3 | -5.5 | -2.5 |
| MIST | 2021-08-24 | 12.0 | 1.3 | -5.6 | -2.6 |
MIST Price Target
For more insight on analysts targets of MIST, see our MIST price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $13.60 | Average Broker Recommendation | 1.4 (Strong Buy) |
MIST Stock Price Chart Interactive Chart >
MIST Price/Volume Stats
| Current price | $5.57 | 52-week high | $8.24 |
| Prev. close | $5.38 | 52-week low | $3.98 |
| Day low | $5.37 | Volume | 16,800 |
| Day high | $5.61 | Avg. volume | 89,419 |
| 50-day MA | $6.26 | Dividend yield | N/A |
| 200-day MA | $6.09 | Market Cap | 166.68M |
Milestone Pharmaceuticals Inc. (MIST) Company Bio
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
Latest MIST News From Around the Web
Below are the latest news stories about Milestone Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIST as an investment opportunity.
Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical OfficerMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer, effective February 15, 2022. Dr. Bharucha is a cardiac electrophysiologist who brings to Milestone over thirty years of global drug development and clinical experience across a range of therapeutic areas, with a focus on cardiovascular medicine. |
Could The Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Ownership Structure Tell Us Something Useful?The big shareholder groups in Milestone Pharmaceuticals Inc. ( NASDAQ:MIST ) have power over the company. Institutions... |
Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual ConferenceMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference being held on January 10-13, 2022. |
Milestone Pharmaceuticals (NASDAQ:MIST) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVTMilestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced new data from a post-hoc analysis of the Phase 3, randomized, double-blind, placebo-controlled NODE-301 trial of etripamil nasal spray, the Company's novel investigational, short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT). The analysis demonstrated that etripamil sig |
MIST Price Returns
| 1-mo | -22.10% |
| 3-mo | -7.93% |
| 6-mo | -8.54% |
| 1-year | -0.89% |
| 3-year | -72.83% |
| 5-year | N/A |
| YTD | -14.96% |
| 2021 | -2.24% |
| 2020 | -58.15% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...